<b style=""><i style="">In-vitro </i>antioxidant properties of</b> <b style="">Indian traditional <i style="">paan </i>and its ingredients </b>

187-191 Indian traditional Paan is being used as a post meal digestive stimulant, astringent, aphrodisiac, nerve tonic, intoxicating agent and for several other purposes in India and is recommended in ancient scriptures of Ayurveda for normal well being. These properties might be due to the antioxidant nature of Paan. Hence, 50% methanol extracts of Paan and its ingredients were screened for antioxidant activity using DPPH method. Catechu, rose powder, betel nut and clove extracts exhibited potent antioxidant properties. Extracts of Paan, betel leaves and fennel showed moderate antioxidant activity. These results confirm the common beliefs and traditional uses of Paan in Indian tradition. </smarttagtype

Marker analysis of polyherbal formulation, Triphala – A well known Indian traditional medicine

379-383Triphala is one of the ages old; most commonly used polyherbal preparation in Indian System of Medicine (ISM) particularly in Ayurveda. A rapid, simple, and accurate method with high performance thin layer chromatography (HPTLC) has been developed to standardize Triphala and its individual component using gallic acid (GA) as analytical marker compound. Methanol extracts of Triphala, Emblica officinalis, Terminalia chebula and Terminalia belerica were used for HPTLC on silica gel plates. The Rf of GA was found to be 0.80 with densitometric scanning at 254 nm and the calibration plot was linear in the range of 400 ng to 1800 ng of GA. The correlation coefficient, 0.999, was indicative of good linear dependence of peak area on concentration. The GA content in Triphala with its individual constituents like Emblica officinalis, Terminalia chebula and Terminalia belerica, was found to be 14.38, 17.50, 16.60 and 11.92 mg g⁻¹. This method permits reliable quantification of GA with good resolution and separation of the same from other constituents of extracts of Triphala and its constituents. Recovery values from 96.86 to 98.71% showed the reliability and reproducibility of the method. The proposed HPTLC method for quantitative monitoring of GA in Triphala and its constituents can be used for routine quality testing and similar methods can be developed for other herbal formulations

Clinical Study of 'Triphala' – A Well Known Phytomedicine from India

Triphala' is an age old commonly used Ayurvedic powdered preparation in Indian systems of medicine. This well known formulation is made by combining Terminalia chebula, Terminalia belarica and Emblica officinalis, in equal proportions based on the observation of Ayurvedic Formulary of India (AFI). The formulation is prescribed in the first line treatment of many aliments and is used as laxative, detoxifying agent and rejuvenator. To establish its clinical validity the present work was undertaken to evaluate its therapeutic potentials and adverse effects. The Triphala formulation was standardized by HPTLC (High Performance Thin Layer Chromatography), using Gallic acid as a marker and was subjected to clinical studies. After proper screening 160 patients of age between 16–52 years were selected for 45 days clinical study. The effectiveness of trial drugs were judged on the basis of the subjective and objective parameters. It was observed that the amount, frequency and consistency of stool were improved in Triphala treated group. The changes of odor, mucous, flatulence, belching and abdominal pain where also taken into account. The well being was assessed on the basis of the parameters like concentration, appetite, thirst, sleep, hyperacidity in arbitrary scoring system. Triphala was found to have good laxative property, help in management of hyperacidity and also improve appetite. No adverse effect was observed in the treated group when compared to normal patients. Triphala can be used effectively in the treatment of constipation and other gastric problems

Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer

Background: Neoadjuvant chemotherapy (NACT) with TPF (docetaxel, cisplatin, and 5FU) is one of the treatment options in very locally advanced oral cancer with a survival advantage over PF (cisplatin and 5FU). TP (docetaxel and cisplatin) has shown promising results with a lower rate of adverse events but has never been compared to TPF. Methods: In this phase 3 randomized superiority study, adult patients with borderline resectable locally advanced oral cancers were randomized in a 1:1 fashion to either TP or TPF. After the administration of 2 cycles, patients were evaluated in a multidisciplinary clinic and further treatment was planned. The primary endpoint was overall survival (OS) and secondary endpoints were progression-free survival (PFS) and adverse events. Results: 495 patients were randomized in this study, 248 patients in TP arm and 247 in TPF arm. The 5-year OS was 18.5% (95% CI 13.8–23.7) and 23.9% (95% CI 18.1-30.1) in TP and TPF arms, respectively (Hazard ratio 0.778; 95% CI 0.637–0.952; P = 0.015). Following NACT, 43.8% were deemed resectable, but 34.5% underwent surgery. The 5-year OS was 50.7% (95% CI 41.5–59.1) and 5% (95%CI 2.9–8.1), respectively, in the surgically resected versus unresected cohort post NACT (P &lt; 0.0001). Grade 3 or above adverse events were seen in 97 (39.1%) and 179 (72.5%) patients in the TP and TPF arms, respectively (P &lt; 0.0001). Conclusion: NACT with TPF has a survival benefit over TP in borderline resectable oral cancers, with an increase in toxicity which is manageable. Patients who undergo surgery achieve a relatively good, sustained survival.</p